UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1277-7
Program Prior Authorization/Notification
Medication Osphena® (ospemifene)
P&T Approval Date 3/2019, 3/2020, 3/2021, 3/2022, 3/2023, 3/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Osphena (ospemifene) is indicated for the treatment of moderate to severe dyspareunia, a
symptom of vulvar and vaginal atrophy due to menopause and for the treatment of moderate to
severe vaginal dryness, a symptom of vulvar and vaginal atrophy (VVA) due to menopause.
2. Coverage Criteriaa:
A. Initial Authorization
1. Benefit designs covering medications to treat sexual dysfunction
a. Osphena will be approved based on the following criteria:
(1) Diagnosis of one of the following:
(a) Treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal
atrophy due to menopause
(b) Treatment of moderate to severe vaginal dryness, a symptom of vulvar and vaginal
atrophy (VVA) due to menopause.
2. Benefit designs excluding medications to treat sexual dysfunction
a. Osphena will be approved based on the following criterion:
(1) Treatment of moderate to severe vaginal dryness, a symptom of VVA due to menopause
Authorization will be issued for 12 months
B. Reauthorization
1. Osphena will be approved based on the following criterion:
a. Documentation of positive clinical response to therapy
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific benefit plan
coverage may also impact coverage criteria. Other policies and utilization management programs may
apply.
© 2025 UnitedHealthcare Services, Inc.
1
3. Additional Clinical Rules:
• Supply limits may be in place
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
4. References:
1. Osphena [package insert]. Princeton, NJ: Duchesnay USA, Inc; February 2024.
Program Prior Authorization/Notification - Osphena
Change Control
Date Change
3/2019 New program
3/2020 Annual review. Updated references.
3/2021 Annual review. No changes.
3/2022 Annual review. No changes.
3/2023 Annual review. Added mandate language.
3/2024 Annual review. Updated references.
3/2025 Annual review. Updated references.
© 2025 UnitedHealthcare Services, Inc.
2